The Effects of RPL554 in Addition to Tiotropium in COPD Patients

Chronic Obstructive Pulmonary Disease Moderate Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03028142
• Other study ID #: RPL554-CO-202
• Status: Completed
• Phase: Phase 2
• Start date: January 2017
• Est. completion date: August 2017

Study information

• Verified date: January 2019
• Source: Verona Pharma plc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II, randomised, double blind, placebo controlled, complete block, three way crossover study to investigate treatment with nebulised RPL554 and tiotropium together in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The purpose of this study is to assess the bronchodilator effect (opening of the airways) of RPL554 when used in combination with a long acting anti-muscarinic receptor antagonist (tiotropium) whilst dosing the RPL554 to steady state blood levels. It is planned to randomise up to 30 patients to have 24 evaluable patients at one study centre. In each treatment period, patients will receive an open label dose of tiotropium from a dry power inhaler (DPI) followed immediately by a double blind dose of either RPL554 6mg, 1.5mg or placebo (depending on treatment sequence) from a nebuliser in the morning on Day 1, Day 2 and Day 3. The dose of RPL554 or placebo will be repeated in the evening on Day 1 and Day 2; there will not be an evening dose on Day 3.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: August 2017
• Est. primary completion date: August 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Sign an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.

2. Male or female aged between 40 and 75 years inclusive, at the time of informed consent.

3. If male: must agree to meet the following from the first dose up to 1 month after the last dose of study treatment:

• Not donate sperm

• Either: be sexually abstinent in accordance with a patient's usual and preferred lifestyle (but agree to abide by the contraception requirements below should their circumstances change) Or: use a condom with all sexual partners. If the partner is of childbearing potential the condom must be used with spermicide and a second highly effective form of contraception must also be used

4. If female: either be:

1. Of non-childbearing potential defined as being:

• Either: post-menopausal (being spontaneously amenorrhoeic for at least 1 year with an appropriate clinical profile [e.g. age appropriate, history of vasomotor symptoms]

• Or: permanently sterilised e.g. tubal occlusion, hysterectomy, bilateral oophorectomy, bilateral salpingectomy

2. Of childbearing potential and agreeing to use a highly effective method of contraception until completion of the end of study visit.

5. Have a 12-lead ECG recording at screening and randomisation (pre-dose in Treatment Period 1) showing the following:

• Heart rate between 45 and 90 beats per minute (bpm)

• QT interval corrected for heart rate using Fridericia's formula (QTcF) =450 msec for males and =470 ms for females

• QRS interval =120 msec

• No clinically significant abnormalities (as judged by the Investigator) including morphology (e.g. left bundle branch block, atrio-ventricular nodal dysfunction, ST segment abnormalities)

6. Have a screening Holter report with a minimum of 18 hours recording that is able to be evaluated for rhythm analysis which shows no abnormality which indicates a significant impairment of patient safety or which may significantly impairs interpretation in the opinion of the Investigator including:

• Significant arrhythmias including atrial flutter, atrial fibrillation, ventricular tachycardia

• Any symptomatic arrhythmia (except isolated extra systoles)

• Any sustained second or third degree heart block

7. Capable of complying with all study restrictions and procedures including ability to use the study nebuliser and HandiHaler® DPI correctly.

8. Body mass index (BMI) between 18 and 33 kg/m2 (inclusive) with a minimum weight of 45 kg.

9. COPD diagnosis: Patients with a diagnosis of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines (Celli and MacNee, 2004) with symptoms compatible with COPD for at least 1 year prior to screening.

10. Post-bronchodilator (four puffs of salbutamol) spirometry at screening:

• Post-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio of =0.70

• Post-bronchodilator FEV1 =40 % and =80% of predicted normal

• Demonstrates =150 mL increase from pre-bronchodilator FEV1

11. Clinically stable COPD in the 4 weeks prior to screening and randomisation (pre-dose in Treatment Period 1).

12. A chest X-ray (post-anterior) at screening, or in the 12 months prior to screening showing no abnormalities, which are both clinically significant and unrelated to COPD.

13. Meet the concomitant medication restrictions and be expected to do so for the rest of the study.

14. Smoking history of =10 pack years.

15. Capable of withdrawing from long acting bronchodilators for the duration of the study, and short acting bronchodilators for 8 hours prior to spirometry.

Exclusion Criteria:

1. A history of life-threatening COPD exacerbation including Intensive Care Unit admission and/or requiring intubation.

2. COPD exacerbation requiring oral steroids, or lower respiratory tract infection requiring antibiotics, in the 3 months prior to screening or randomisation (pre-dose in Treatment Period 1).

3. A history of one or more hospitalisations for COPD in the 12 months prior to screening or randomisation (pre-dose in Treatment Period 1).

4. Lactation (female patients only).

5. Positive urine or serum pregnancy test at screening, or a positive urine pregnancy test prior to randomisation (female patients of childbearing potential only).

6. Prior exposure to RPL554 or known hypersensitivity to RPL554 or its components.

7. Intolerance or hypersensitivity to tiotropium.

8. Evidence of cor pulmonale.

9. Other respiratory disorders: Patients with a current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, sleep apnoea, known alpha-1 antitrypsin deficiency or other active pulmonary diseases.

10. Previous lung resection or lung reduction surgery.

11. Use of oral COPD medications (e.g. oral steroids, theophylline and romifulast) in the 3 months prior to screening or randomisation (pre-dose in Treatment Period 1).

12. History of, or reason to believe, a patient has drug or alcohol abuse within the past 3 years.

13. Inability to perform technically acceptable spirometry or whole body plethysmography (at screening or randomisation [pre dose in Treatment Period 1])

14. Received an experimental drug within 30 days or five half lives, whichever is longer.

15. Patients with a history of chronic uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, haematological, urological, immunological, or ophthalmic diseases that the Investigator believes are clinically significant.

16. Documented cardiovascular disease: arrhythmias, angina, recent or suspected myocardial infarction, congestive heart failure, a history of unstable, or uncontrolled hypertension, or has been diagnosed with hypertension in the 3 months prior to screening or randomisation.

17. Concurrent use of non-cardioselective oral beta-blockers.

18. Has had major surgery, (requiring general anaesthesia) in the 6 weeks prior to screening or randomisation (pre-dose in Treatment Period 1), or will not have fully recovered from surgery, or planned surgery through the end of the study.

19. A disclosed history or one known to the Investigator, of significant non compliance in previous investigational studies or with prescribed medications.

20. Requires oxygen therapy, even on an occasional basis.

21. Clinically significant prostatic hyperplasia (judged by the Investigator) or bladder-neck obstruction or with narrow-angle glaucoma.

22. Any other reason that the Investigator considers makes the patient unsuitable to participate.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease Moderate
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• 1.5 mg RPL554 plus tiotropium

• 6 mg RPL554 plus tiotropium

• Placebo plus tiotropium

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Verona Pharma plc

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak Forced Expired Volume in 1 Second (FEV1) on the Third Day of Dosing	Peak forced expired volume in 1 second (FEV1) over 4 hours on the third day of dosing	Day 3
Primary	Average FEV1 Over 12 Hours on the Third Day of Dosing	Average FEV1 area under the curve (AUC) over 12 hours on the third day of dosing	Day 3
Secondary	Peak FEV1 on Day 1	Peak FEV1 over 4 hours on Day 1	Day 1
Secondary	Average FEV1 Over 12 Hours on Day 1	Average FEV1 AUC over 12 hours on Day 1	Day 1